02185.HK
Shanghai Bio-heart Biological Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 0.93
−3.63%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 58.7M | 43.8M | — | — | — |
| Cost of Revenue | 49.9M | 43.9M | — | 23.6M | 24.3M |
| Gross Profit | 8.8M | (157.8K) | — | (23.6M) | (24.3M) |
| Operating Expenses | |||||
| R&D Expense | 114.2M | 58.2M | 41.3M | 111.7M | 168.7M |
| SG&A Expense | 34.7M | 11.5M | 19.7M | 16.1M | 100.3M |
| General & Admin Expense | 22.3M | — | 19.7M | 16.1M | 13.3M |
| Selling & Marketing Expense | 1.1M | — | — | — | 87.0M |
| Other Expenses | — | — | — | 18.4M | — |
| Total Operating Expenses | 148.9M | 69.7M | 61.0M | 146.3M | 269.0M |
| Cost and Expenses | 198.7M | 113.6M | 61.0M | 164.6M | 293.3M |
| Operating Income (EBIT) | (140.0M) | (69.8M) | (61.0M) | (164.6M) | (293.3M) |
| Non-Operating | |||||
| Interest Income | 3.2M | 2.0M | 1.0M | 4.0M | 4.0M |
| Interest Expense | 13.7M | 8.5M | — | 578.0K | 959.0K |
| Net Interest Income | (10.5M) | (6.6M) | 1.0M | 3.4M | 3.1M |
| Other Non-Op Income/Expense | (52.7M) | (23.7M) | (32.3M) | (24.2M) | 26.5M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (192.8M) | (93.5M) | (93.3M) | (188.8M) | (266.8M) |
| Income Tax Expense | (25.9M) | (26.9M) | — | 5.5M | (29.3M) |
| Bottom Line | |||||
| Net Income | (163.7M) | (68.2M) | (87.9M) | (175.9M) | (204.2M) |
| Earnings from Cont. Ops | (165.5M) | (66.7M) | (93.3M) | (188.8M) | (230.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (163.7M) | (68.2M) | (87.9M) | (175.9M) | (237.5M) |
| Per Share | |||||
| Basic EPS | (HK$0.68) | (HK$0.28) | (HK$0.36) | (HK$0.72) | (HK$0.98) |
| Diluted EPS | (HK$0.68) | (HK$0.28) | (HK$0.36) | (HK$0.72) | (HK$0.98) |
| Revenue Per Share | HK$0.24 | HK$0.18 | HK$0.00 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 243.4M | 243.4M | 243.4M | 243.4M | 243.4M |
| Diluted Shares Outstanding | 243.4M | 243.4M | 243.4M | 243.4M | 243.4M |
| Profitability Metrics | |||||
| EBITDA | (107.6M) | (52.1M) | (52.9M) | (143.3M) | (229.4M) |
| D&A | 32.4M | 17.7M | 8.2M | 21.4M | 20.9M |
| EBIT | (140.0M) | (69.8M) | (61.0M) | (164.6M) | (250.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026